Europe
Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.
It was a very busy week for clinical trial updates. Here’s a look.
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the vaccine should it be approved, as well as a late-stage efficacy study in that country.
Niclosamide is an oral anthelminthic drug. It was first approved by the U.S. Food and Drug Administration (FDA) in 1982 and is included in the World Health Organization (WHO)’s list of essential medicines.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
Biopharma and life sciences companies bolster their executive ranks and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
According to a study published in Nature Communications on August 11, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
While Russian President Vladimir Putin expressed confidence in the preventative medication against the novel coronavirus, scientists from across the globe expressed concern over the lack of available data.
PRESS RELEASES